Study: Dutasteride Mesotherapy Accelerates Hair Loss in Female Patients with Metabolic Syndrome Finasteride/Dutasteride 3/16/2024
Dutasteride mesotherapy in women with metabolic syndrome accelerated hair loss after initial regrowth, while women without metabolic syndrome saw continuous regrowth. The user with mild insulin resistance is hesitant to try topical dutasteride and seeks experiences from others with insulin resistance.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Joined the Dutasteride Master Race
Dutasteride and finasteride are discussed for hair loss treatment, with users sharing experiences and debating their effectiveness and side effects. Celebrities are noted as common users, and there is debate over which treatment is superior.
community Is DUT better or worse than FIN?
The conversation discusses the effectiveness of Dutasteride (DUT) and Finasteride (FIN) for hair loss. Users share varied experiences, with some finding DUT more effective and others experiencing side effects or no change, highlighting that individual responses can vary.
community Everyone is ignoring that plasma finasteride levels are 100x lower with topical compared to oral.
Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.
community How is there zero improvement with finding the cure?
Hair loss treatments have not advanced since 2018, with finasteride, minoxidil, and RU58841 still being the main options. A permanent cure is unlikely due to the profitability of ongoing treatments.
community Dutasteride 1mg or RU58841 8% or topical Dutasteride
The discussion focuses on hair loss treatments, with suggestions to increase oral Dutasteride to 1 mg or more, as topical Dutasteride is less effective. Other treatments mentioned include RU58841, Minoxidil, and dermastamping, with some users recommending injectable mesotherapy and topical Finasteride.
Related Research
6 / 6 resultsresearch 5α-Reductase inhibitors alter steroid metabolism and may contribute to insulin resistance, diabetes, metabolic syndrome and vascular disease: a medical hypothesis
This report advances the hypothesis that finasteride and dutasteride inhibit 5α-reductase activities, potentially altering steroid metabolism and increasing the risk of insulin resistance, diabetes, and vascular disease.
research Polycystic Ovary Syndrome: A Common Reproductive and Metabolic Disorder Necessitating Early Recognition and Treatment
This article reviews the challenges in treating PCOS, noting the potential benefits of insulin sensitizers on ovulatory function and pregnancy outcomes, and calls for more long-term studies on metabolic interventions.
research American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome - Part 1
This review discusses the diagnostic criteria and management strategies for Polycystic Ovary Syndrome (PCOS) and highlights the need for comprehensive clinical assessment, but does not report new clinical findings.
research Síndrome do ovário policístico: abordagem dermatológica
This review discusses the pathophysiology, diagnosis, and treatment of polycystic ovary syndrome, emphasizing the critical importance of early diagnosis and treatment to prevent metabolic complications and improve quality of life.
research A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome
This study of FAERS data suggests that finasteride, particularly at the 1 mg dosage, is associated with a wide range of adverse effects not previously established in long-term studies, especially among younger men.
research Androgenetic Alopecia in Polycystic Ovary Syndrome: A Cutaneous Marker of Systemic Metabo-inflammatory and Endocrine Dysfunction: A Narrative Review
This review posits that alopecia in PCOS results from the interaction between local follicular signaling failures, insulin resistance, inflammation, and genetic predispositions, rather than solely from androgen excess, and recommends a systems-level framework for its management.